June 23, 2021 – Page 2 – Emirates Press

June 23, 2021

CadencyDirect, the Only Native Built on Now App for the ServiceNow Platform for the Financial Close, Extends Digital Workflows for the Office of the CFO

CadencyDirect by Trintech Continues to Drive Value for ServiceNow Customers by Providing Key Stakeholders across the Enterprise with Full Visibility into Critical Financial Data

DALLAS, TX / ACCESSWIRE / June 23, 2021 / Trintech, a leading global provider of integrated Record to Report software solutions for the Office of Finance, today announced the latest release of CadencyDirect, is now certified as part of the ServiceNow Built on Now™ program that complements and extends financial operations management so that CFOs and their teams can digitize workflows across the Record to Report (R2R) close process – helping to reduce complexity and risk, accelerating the overall process, and driving a greater experience for the entire enterprise. CadencyDirect has met the high standards of the ServiceNow Built on Now program, an app monetization framework designed to recognize partners with proven ServiceNow expertise that creates value for ServiceNow customers across industries.

“Accounting is the language of business and that information is not only critical to the Office of Finance, but to the entire enterprise,” said Teresa Mackintosh, CEO of Trintech. “With the latest release of CadencyDirect, key stakeholders across the business will now have the visibility and transparency into key financial data and how it relates to the entire organization all within the Now Platform.”

“Over the past year, we have seen companies reassessing digital transformation opportunities, specifically how to manage key financial processes,” said CJ Desai, Chief Product & Engineering Officer at ServiceNow. “CadencyDirect builds workflows between historically siloed disciplines by linking and automating the financial close process, while illuminating key data through R2R dashboard views within the Now Platform. This enhanced visibility into critical financial data creates a connected organization that opens the door to enterprise-wide transformation and is why we have partnered with Trintech to drive workflows for the Office of the CFO.”

CadencyDirect is built on Trintech’s industry-leading Cadency^® solution that combines all financial close activities into a single, seamless process, including operational matching, intercompany transaction management, balance sheet reconciliations, journal entry management, close task management, and compliance. It provides a connected, collaborative ecosystem by leveraging a mature and very robust set of financial controls, along with deep automation and integration capabilities that seamlessly connects with leading ERPs such as SAP^®, Oracle^®, and NetSuite^®.

Very rarely is there a process that occurs entirely within the jurisdiction of one team. When it comes to workflows for the CFO, CadencyDirect enables users to leverage workflows within the Now Platform based on triggers and events in the period-end close – strengthening financial controls across the enterprise. As an example, when an account is certified in CadencyDirect, a task is triggered in the ServiceNow platform to the FP&A team to accelerate the review of certified balances to analyze period-specific differences or impacts to forecasting the coming periods.

The ServiceNow Built on Now program empowers partners to build, test, certify, distribute and sell applications for the Now Platform®. Built on Now-designated solutions deliver Now Certified digital workflows for the Now Platform, at scale, through the ServiceNow Store, OEM, and Service Provider (SP) channels.

Whether you’re an experienced ServiceNow user looking to synchronize your mature or in-progress digital transformation, or just starting your transformation journey, CadencyDirect is where Finance Transformation meets Digital Transformation. For more information, please contact either your appropriate ServiceNow or Trintech representative or go to www.trintech.com/CadencyDirect for more information.

About Trintech

Trintech Inc., a pioneer of Financial Corporate Performance Management (FCPM) software, combines unmatched technical and financial expertise to create innovative, cloud-based software solutions that deliver world-class financial operations and insights. From high volume transaction matching and streamlining daily operational reconciliations, to automating and managing balance sheet reconciliations, intercompany accounting, journal entries, disclosure reporting, and bank fee analysis, to governance, risk, and compliance – Trintech’s portfolio of financial solutions, including Cadency^® Platform, Adra^® Suite, and targeted tools, ReconNET™, T-Recs^®, and UPCS^®, help manage all aspects of the financial close process. Over 3,500 clients worldwide – including the majority of the Fortune 100 – rely on the company’s cloud-based software to continuously improve the efficiency, reliability, and strategic insights of their financial operations.

Headquartered in Dallas, Texas, Trintech has offices located across the United States, United Kingdom, Australia, Singapore, France, Germany, Ireland, the Netherlands, and the Nordics, as well as strategic partners in South Africa, Latin America, and the Asia Pacific. To learn more about Trintech, visit www.trintech.com or connect with us on LinkedIn, Facebook, and Twitter.

ServiceNow, the ServiceNow logo, Now, Now Platform, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries.

Media Contact:
Kristina Pereira Tully
Vested
650-464-0080
trintech@fullyvested.com

SOURCE: Trintech, Inc.

June 23, 2021

RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy

Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke

MIAMI, June 23, 2021 (GLOBE NEWSWIRE) — RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced the closing of a $15 million Series A financing. The financing was led by Santé Ventures who was joined by Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon. RapidPulse plans to use the proceeds to advance its RapidPulse™ Cyclic Aspiration System through expanded clinical evaluation and build out its platform of proprietary catheters.

The RapidPulse™ system was developed by Syntheon, a medical device incubator focused on developing next generation medical devices. Their various products, commercialized by the largest and most trusted medical device companies in the world, have treated over 50 million patients globally in applications ranging from laparoscopic surgery, cardiovascular, and flexible endoscopy. Syntheon has over 200 issued patents since its inception over 20 years ago.

“We are pleased to have partnered with an outstanding investor syndicate to move our RapidPulse™ technology forward in the clinic,” said Sean McBrayer, CEO of Syntheon who will also serve as initial CEO of RapidPulse. “Stroke is the second leading cause of death and the third leading cause of disability worldwide, and minutes matter in improving these outcomes. This investment will help us expand our clinical results and move towards regulatory approval in the United States.”

Joining the team are industry veterans Heather Harries and Cynthia Yang. Heather most recently served as General Manager for Terumo’s aortic business and will lead product development and operations for RapidPulse. Cynthia will lead clinical development for the company, after most recently working in the neurovascular division of Medtronic.

Dennis McWilliams, partner at Santé Ventures, added, “Heather and Cynthia bring exceptional domain expertise to the team at RapidPulse, and will complement the significant engineering development experience at Syntheon. RapidPulse is a disruptive platform opportunity in neurovascular, and has the potential to significantly improve patient outcomes for ischemic stroke patients.”

ABOUT RAPIDPULSE

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry. Visit www.rapidpulsemed.com for more information.

ABOUT SANTÉ VENTURES

Santé Ventures is a life sciences investment firm that invests in early-stage companies in medical device, biotechnology, and digitally enabled health services. We partner with entrepreneurs to build impactful companies, including Claret Medical (now part of Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), and Molecular Templates (NASDAQ: MTEM). Founded in 2006, Santé has just under $1 billion in assets under management, and has offices in Austin, TX and Boston, MA. For more information, please visit sante.com.

ABOUT EPIDAREX CAPITAL

Epidarex Capital is a transatlantic venture capital firm that builds exceptional life science companies in emerging hubs in the US and UK. Epidarex’s experienced team of early-stage investors partner with entrepreneurs and leading research institutions to transform world-class science into highly innovative products addressing major unmet needs in global healthcare. For more information, please visit www.epidarex.com

ABOUT HATTERAS VENTURE PARTNERS

Founded in 2000 and based in Durham, NC, Hatteras Venture Partners is a venture capital firm with a focus on seed and early stage healthcare investing. Through six funds and over $600 million under management, the firm has invested in breakthrough science and entrepreneurial grit in the areas of biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. To learn more, please visit www.hatterasvp.com.

ABOUT BROADVIEW VENTURES

Founded in 2008, Broadview Ventures is a mission-driven investment organization. Broadview’s primary goal is to improve human health in the areas of cardiovascular disease and stroke through investments in early stage companies developing innovative therapeutics, devices, and diagnostics. For more information about Broadview Ventures, visit broadviewventures.org.

MEDIA CONTACT:

Sean McBrayer, info@rapidpulsemed.com, 305-266-3388

June 23, 2021

‫تُقدم شركة Space Perspective الرائدة أول تجربة رحلات فاخرة إلى الفضاء في العالم حتى تُعيد تخيل إثارة استكشاف الفضاء

يعرض الإطلاق التجريبي لسفينة الفضاء نبتون وان في فلوريدا مناظر خلابة من الفضاء ويُنذر بفرصة لحجز مقعدك الآن لعام 2024

نيويورك, 23 يونيو 2021 /وكالة أنباء PR/ — تقديم حقبة جديدة في تجارب السفر الفاخر: Space Perspective هي الرحلة الأكثر جمالًا في العالم إلى الفضاء. يمكن لمغامري السفر الآن حجز مقعد على سفينة الفضاء نبتون والاستمتاع بإطلالات بزاوية 360 درجة تطل على كوكب الأرض من ارتفاع 20 ميلاً/ 30 كم في رحلة فاخرة مدتها ست ساعات. يمكن لما يصل إلى ثمانية ضيوف الاستمتاع بكبسولة مجهزة بشكل جميل، ومزودة بـ بار وحمام، مقابل 125,000 دولار لكل منهما.

عبر اتباع بنات أفكار خبراء السفر إلى الفضاء جين بوينتر وتابر ماك كالوم، تريد Space Perspective أن يختبر المزيد من الأشخاص مناظر تغير الحياة من الفضاء والتي لم يكن الوصول إليها متاحًا حتى الآن إلا لرواد الفضاء – مما يجعل ذلك ممكنًا من خلال تطبيق تقنية الطيران التي تستخدمها ناسا على نطاق واسع لسنوات عديدة .

هذه الفرصة التحويلية، التي تتيح الحجوزات الآن للرحلات الجوية في وقت قريب في أواخر عام 2024، توسع من إمكانية استكشاف الفضاء لقطاع أكبر من الجمهور مما كان ممكنًا تاريخيًا. وللأشخاص الفضوليين حول استكشاف الفضاء الذين كانوا يعتبرون الأمر محفوفًا بالمخاطر أو باهظ التكلفة يمكنهم الآن تجربة سفر مليئة بالفرح إلى الفضاء بصعود آمن ولطيف. وتتمكن المركبة الفضائية الغير مسبوقة نبتون والتي تعمل بالضغط من نقل الركاب برفق إلى الفضاء لتعرض مناظر خلابة أثناء دورانها في منحنيات الأرض.

سيصعد مستكشفو الفضاء الذين يصنعون التاريخ في سفينة الفضاء نبتون من منصة الإطلاق في مركز كينيدي للفضاء الشهير. وسيُحلق ثمانية ضيوف، برفقة طيار، فوق 99٪ من الغلاف الجوي للأرض ثم ينحدرون لمدة ساعتين للاستمتاع بتجربة فريدة بالمحيط الحيوي لكوكبنا من نوافذ المشاهدة الواسعة للكبسولة المريحة.

على عكس الصواريخ الفضائية الشاقة والمكلفة ماديًا، تعيد المركبة الفضائية نبتون كتابة قواعد اللعبة الهندسية: فهي لا تستخدم الدفع الصاروخي ولا تسارع قوة الجاذبية. تبعث على البهجة بحد ذاتها، هذه التجربة تدعو إلى منظور مختلف تمامًا عندما تأخذك خلال طبقات الغلاف الجوي، مؤطرًا بالخط الأزرق الرفيع أدناه وسواد الفضاء أعلاه. هذا التذكير العميق بمدى ارتباطنا مع جميع الكائنات الحية – وفقًا لمعظم رواد الفضاء الذين جربوه – يغير الحياة بشكل عميق؛ ويعمل على تلاشي الحدود والاختلافات.

سيتم تنظيم كل رحلة بشكل شخصي من خلال برامج توفر تجارب حسب الطلب من البداية إلى النهاية، بدءًا من لقاء رواد الفضاء المشاهير وحتى اصطحاب حفلات الزفاف إلى آفاق جديدة.

Space Perspective هي أول شركة إطلاق مركبات فضائية تطير من Space Coast Air وميناء فضائي، ويقعا بالقرب من مركز كينيدي للفضاء التابع لناسا في فلوريدا. بدأت رحلة اختبار نبتون وان الافتتاحية لبرنامج اختبار مكثف يجعل من سفينة الفضاء نبتون طريقة آمنة للغاية للسفر إلى الفضاء. تضمن Space Perspective السلامة من خلال تطبيق تكنولوجيا الطيران التي استخدمتها ناسا والهيئات الحكومية العالمية لعقود من الزمن، بدعم من طاقم عالمي تم اختياره بعناية كجزء لا يتجزأ من جميع رحلات بالون الفضاء البشرية على مدار الخمسين عامًا الماضية.

تسعى جين بوينتر وتابر ماك كالوم، الزوجان وراء فكرة Space Perspective، في مهمة لدعوة المزيد من الناس – بما في ذلك العلماء والفنانين – لركوب موجة تاريخ الفضاء وتحويل وجه التاريخ من خلال رؤية أرضنا الجميلة من الفضاء.

يعزي الفضل إلى الزوجين في الكشف عن بعض الإنجازات الأكثر بروزًا في مجال ابتكار واستكشاف الفضاء في العشرين عامًا الماضية: إتقان التقنيات التي شوهدت في محطة الفضاء الدولية، والعمل كمستشارين تقنيين في رحلات الفضاء البشرية التابعة لـ إيلون ماسك قبل تأسيسه لشركة سبيس إكس، وتحقيق الرقم القياسي العالمي للمدير التنفيذي لشركة جوجل آلان إيوستاس لرحلات الفضاء البشرية – 136,000 قدم مدفوعة بواسطة بالون فضاء في عام 2014.

السفر إلى الأماكن التي لم يسبق لها مثيل من قبل بإطار يُتيح الوصول إليها بالكامل، تضع Space Perspective معيارًا جديدًا في تجارب الرفاهية خارج هذا العالم. يُرجى زيارة www.spaceperspective.com لحجز مقعدك.

Instagram @thespaceperspective

Twitter @SpacePerspectiv

Facebook @TheSpacePerspective

Space Perspective

Space Perspective هي تجربة السفر للفضاء الأكثر رفاهية في العالم. وهي تدعو أشخاصًا أكثر مما سبق على مدار التاريخ لتجربة منظور جديد ومثير للدهشة يعمل على توسيع أفاق الوعي البشري – عبر الصور البانورامية المبهجة بشكل لا يصدق وحجم الأرض من الفضاء. يمتد غلافنا الجوي لمئات الأميال في الفضاء، وتطير المركبة الفضائية نبتون لتغطي 99٪ منه.

تثبيت قدم جديدة في التجارب المثيرة خارج هذا العالم، بحلول أواخر عام 2024، سترافق Space Perspective مستكشفي الفضاء في رحلة سلسة إلى الفضاء داخل كبسولة نبتون التي تعمل بالضغط ويتم دفعها ببالون فضاء عالي الأداء ولا تعتمد على استخدام وقود الصواريخ، وسيتمكن المستكشفون من مشاهدة العالم من آفاق جديدة من خلال نوافذه الواسعة. تعيد الرحلة المريحة للغاية التي أصبحت في متناول الجميع والتي تستغرق ست ساعات تحديد معنى السفر إلى الفضاء والعجائب التي سيتمتع بها المسافر العصري.

انطلاقاً من مركز كينيدي للفضاء، سيقود رحلة Space Perspective جين بوينتر وتابر ماكالوم، النجمان البارزان في هذا المجال، وطاقمهما الخبير الذي كان جزءًا لا يتجزأ من جميع رحلات بالون الفضاء البشرية في الخمسين عامًا الماضية. أطلق على بوينتر وماكالوم لقب “سادة طبقة الاستراتوسفير” من قبل بلومبيرغ بيزنس ويك، وشغل ماكالوم منصب رئيس اتحاد رحلات الفضاء التجارية.

صورة – https://mma.prnewswire.com/media/1538674/Space_Perspective.jpg

صورة – https://mma.prnewswire.com/media/1538675/Space_Perspective_Logo.jpg

June 23, 2021

Conformis, Inc. Announces Exclusive Distribution Agreement in China

New Agreement expands Conformis’ global reach and brings patient-specific knee replacement systems to the largest market in the Asia-Pacific region

BILLERICA, Mass., June 23, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) today announced the execution of an agreement to enter the Asia-Pacific market through an exclusive distribution relationship with XR Medical Group (Hong Kong) Limited (XR Medical).

Under the distribution agreement, XR Medical will have exclusive rights for the sale, marketing, and distribution of Conformis’ patient-specific iTotal^® CR & PS total knee replacement systems, iTotal^® CR & PS patella devices, and iUni^® and iDuo^® partial knee replacement systems. Other products, such as Conformis’ recently approved Identity Imprint™ knee system and its hip portfolio of products, may be added in the future.

XR Medical’s sales team will provide sales and support exclusively to top-tier facilities in Hainan’s Boao Lecheng International Medical Tourism Pilot Zone (Pilot Zone) on behalf of Conformis. The region is a major center of medical tourism for dozens of countries.

“This distribution agreement is another example of progress as we execute our overall growth strategy. We are confident that our unique product portfolio will serve to accelerate Conformis’ international growth. And we are pleased to partner with XR Medical, which has an impressive track record of success in China,” said Mark Augusti, President and CEO of Conformis. “What is particularly attractive about XR Medical is its strong performance in the Pilot Zone. With access to patients visiting the region for treatment, this creates an opportunity to introduce a broad audience to the clinical benefits of Conformis technology. We believe that starting in the Pilot Zone positions us well and we anticipate that this relationship will serve as a model for future expansion opportunities in mainland China.”

The Pilot Zone is located on Hainan, a large island off China’s southern coast. It was established in 2019 to attract affluent Chinese citizens who might otherwise go abroad for their medical care. This region of China has developed top-level medical treatment facilities in a popular destination. Currently, medical tourists from dozens of countries, including those in Southeast Asia, are permitted to visit Hainan for a 30-day stay without visas.

The global market for knee joint reconstruction is projected at more than $9 billion. Of this total, the knee joint reconstruction market in the Asia-Pacific region is currently estimated to exceed $1.7 billion. Fortune Business Insights predicts a high growth rate for knee replacements in the region due to the combination of the increased prevalence of knee disorders, booming medical tourism, increased disposable incomes, and improved healthcare infrastructure.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit^® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit and conform to each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and standard implants, along with single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal^® CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release about our future expectations, plans and prospects, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. You should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Source: Conformis, Inc.

Media Contact:
Investor Relations
ir@conformis.com
(781) 374-5598

June 23, 2021

Dante Labs acquires Cambridge Cancer Genomics to create global excellence in precision oncology

Integrated single software platform will enable true patient-centric precision oncology at scale for cancer patients care combining medical, germline, somatic and liquid biopsy data analysis together.
Cambridge Cancer Genomics OncOS machine learning oncology software will be integrated in Dante Labs CE-IVD, ISO13485 Immensa Genomics Interpretation Software, and it will become available to clinical and research customers in the summer.
The combined solution addresses an estimated $75 billion market opportunity.

CAMBRIDGE, United Kingdom, June 23, 2021 (GLOBE NEWSWIRE) — Dante Labs, a leading genomics and diagnostics company, today announced the acquisition of Cambridge Cancer Genomics (CCG.ai), a groundbreaking Y-Combinator company & leader in machine learning for clinical oncology, to create a single platform with unparalleled capabilities in genomics and oncology data analysis.

“Matching cancer patients to the best therapy has been a longstanding problem in the field of oncology,” says Dr John W Cassidy, CEO and cofounder of CCG.ai, “CCG.ai was founded on the premise that every patient should be on the right treatment, at the right time, to beat their cancer. Since that founding moment, the team has dedicated themselves to state-of-the-art software development and fundamental research in tumour evolution, treatment response and A.I., to enable better deployment of targeted therapies for all. Now, with Dante Lab’s commercial reach and expertise in direct-to-consumer genomic testing, our products will be even closer to where they can make the ultimate impact – in the lives of patients.”

“Few companies have produced meaningful clinical data of the use of machine learning for the analysis and interpretation of genomics and medical data in clinical oncology,” says Dante Labs CEO Andrea Riposati, “Cambridge Cancer Genomics is in a class of its own. In these past years, the team has developed very smart tools for oncology that make a true difference in the lives of patients. The data is impressive and we look forward to implementing OncOS globally.”

Integration of biology and tech
Broad adoption of precision medicine has been limited by the lack of integration of technology and biology in a single platform. Machine learning requires the generation of proprietary longitudinal, multi-omics data and a very fast feedback loop from the clinical laboratory.

With this new acquisition, Dante Labs will provide clinical organizations with end-to-end oncology solutions to make decisions that have an impact in the lives of the patients.

Dante Labs Immensa software received CE-IVD Mark and ISO13485 Certificate for Medical Devices in 2021.
Dante Labs end-to-end research and clinical solutions have helped people in 97 different countries, providing insights in rare diseases, infectious diseases and preventive medicine.
Dante Labs is hiring a stellar medical team with years of experience in oncology, pediatric cancers and precision medicine.
CCG.ai pipelines for data-set generation and transformation pioneered the use of -omics data to machine learning.
CCG.ai OncOS precision oncology software platform drives real life decisions to ensure data-driven cancer treatment for all patients.

About CCG.ai
Cambridge Cancer Genomics (CCG.ai) was founded to ensure that each patient has the right drug, at the right time, to beat their cancer. We build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response. At CCG.ai we believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions about which drug to use in which circumstance.

About Dante Labs
Dante Labs’ mission is to make the most advanced genomic technologies accessible to everyone. To date, it has customers in more than 95 countries who have personally experienced the power of the whole genome. Dante Labs is also a global provider of COVID-19 testing solutions for governments, businesses and individuals to help people get back safely to normal life. To learn more or to purchase a Dante Labs whole genome sequencing or COVID-19 test, visit www.dantelabs.com and follow @DanteLabs.

Giorgio Lodi, giorgio.lodi@dantelabs.com. +39 0862 191 0671

June 23, 2021

‫ شركة Unilumin أول شركة LED صينية تحصل على اعتماد نظام السينما الرقمية

شنجن، الصين، 23 يونيو 2021 / PRNewswire / — اجتازت أحدث شاشة عرض سينمائي من إنتاج شركة Unilumin مؤخرًا اختبارات معهد أبحاث وسائل الإعلام الرقمية والمحتوى (DMC) ، في جامعة كيو، وهي وكالة معتمدة من نظام السينما الرقمية (DCI) ، وأصبحت رسميًا منتجًا حاصلًا على اعتماد نظام السينما الرقمية. وهكذا أصبحت شركة Unilumin أول شركة متخصصة في إنتاج شاشات عرض LED في الصين تحصل على شهادة نظام السينما الرقمية لتكتسب بذلك وصولاً كاملاً إلى الفرص المتاحة في سوق شاشات عرض LED السينمائية.

ما هي شهادة نظام السينما الرقمية المعتمدة دوليًا؟

نظام السينما الرقمية هي منظومة من مواصفات نظام السينما الرقمية تركز على تطوير البرامج الهندسية المفتوحة. لا يمكن تطبيق أنظمة الأفلام الرقمية أو المنتجات التي لا تحمل شهادة نظام السينما الرقمية أو الترويج لها في سوق السينما. حصلت شاشة العرض السينمائي من إنتاج شركة Unilumin على اعتماد نظام السينما الرقمية، لتعكس بذلك تقنيتها الرائدة عالميًا في شاشات عرض LED السينمائية!

هذا وتقدم أحدث شاشة سينمائية من Unilumin أداء عرض متميز بدقة 4K تبلغ 4096*2160 ونطاق ألوان DCI-P3 ونسبة تباين فائقة تبلغ 40000:1. يتميز هذا المنتج بمستوى توطين عالي للغاية، يمكن أن يحقق التحكم المستقل في السلسلة الصناعية ويقلل التكلفة بشكل كبير، مما يضع أساسًا متينًا لتعميم شاشات عرض LED السينمائية واستخدامها.

توجهات تطوير السينما وشاشات العرض السينمائي عالية الجودة

من المتوقع أن يتم استبدال أكثر من 100,000 شاشة سينما مثبتة على مدار السنوات الخمس المقبلة بعد 2020، حسبما كشفت شركة TrendForce مستشهدة بتحليل شركة Barco الرائدة في مجال إنتاج أجهزة العرض السينمائي لاتجاهات السينما من عام 2006 إلى عام 2026. نظرًا للمنافسة الشرسة في سوق السينما، سيكون هناك ما مجموعه 200,000 شاشة سينما بحلول عام 2023. يمكن لشاشات LED أن تتوافق بسهولة مع اتجاه عرض الصور، الذي لا بد أن يكون عالي الدقة مثل 4K أو حتى 8K ، وتوفر أجهزة عرض الليزر دقة فائقة وقدرات عرض عالية التدفق الضوئي، لذا فهي تخترق سوق السينما تدريجياً.

حضور شامل واستكشاف مستمر

عملت شركة Unilumin ، باعتبارها أحد رواد صناعة شاشات LED ، منذ فترة طويلة في سوق شاشات العرض السينمائية. من ناحية، فقد أولت شركة Unilumin اهتمامًا للتكامل المتعمق لتقنيات 5G ، و 4K/8K ، و 3D وغير ذلك من تقنيات الأفلام عالية الجودة، وروجت بفاعلية استخدام شاشات LED في دور السينما.

ومن ناحية أخرى، فقد نفذت شركة Unilumin تعاونًا خارجيًا على نحو فعال، مما عزز بشكل كبير التطوير المشترك ووضع أساسًا سوقيًا كافيًا لازدهار صناعة شاشات عرض LED السينمائية.

هذا ويمثل اعتماد نظام السينما الرقمية أحدث إنجازات لجهود Unilumin في سوق شاشات العرض السينمائية. في المستقبل، ستقدم شركة Unilumin للأشخاص حياة أفضل للوسائط السمعية والبصرية مع صور عرض عالية الجودة وتجربة مشاهدة غامرة.

الصورة – https://mma.prnewswire.com/media/1534376/image.jpg